Cargando…
Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites
BACKGROUND: Psoriasis is a cytokine-mediated skin disease that can be treated effectively with immunosuppressive biologic agents. These medications, however, are not equally effective in all patients and are poorly suited for treating mild psoriasis. To develop more targeted therapies, interfering w...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392043/ https://www.ncbi.nlm.nih.gov/pubmed/25883770 http://dx.doi.org/10.1186/s40169-015-0054-5 |
_version_ | 1782365914969145344 |
---|---|
author | Swindell, William R Sarkar, Mrinal K Stuart, Philip E Voorhees, John J Elder, James T Johnston, Andrew Gudjonsson, Johann E |
author_facet | Swindell, William R Sarkar, Mrinal K Stuart, Philip E Voorhees, John J Elder, James T Johnston, Andrew Gudjonsson, Johann E |
author_sort | Swindell, William R |
collection | PubMed |
description | BACKGROUND: Psoriasis is a cytokine-mediated skin disease that can be treated effectively with immunosuppressive biologic agents. These medications, however, are not equally effective in all patients and are poorly suited for treating mild psoriasis. To develop more targeted therapies, interfering with transcription factor (TF) activity is a promising strategy. METHODS: Meta-analysis was used to identify differentially expressed genes (DEGs) in the lesional skin from psoriasis patients (n = 237). We compiled a dictionary of 2935 binding sites representing empirically-determined binding affinities of TFs and unconventional DNA-binding proteins (uDBPs). This dictionary was screened to identify “psoriasis response elements” (PREs) overrepresented in sequences upstream of psoriasis DEGs. RESULTS: PREs are recognized by IRF1, ISGF3, NF-kappaB and multiple TFs with helix-turn-helix (homeo) or other all-alpha-helical (high-mobility group) DNA-binding domains. We identified a limited set of DEGs that encode proteins interacting with PRE motifs, including TFs (GATA3, EHF, FOXM1, SOX5) and uDBPs (AVEN, RBM8A, GPAM, WISP2). PREs were prominent within enhancer regions near cytokine-encoding DEGs (IL17A, IL19 and IL1B), suggesting that PREs might be incorporated into complex decoy oligonucleotides (cdODNs). To illustrate this idea, we designed a cdODN to concomitantly target psoriasis-activated TFs (i.e., FOXM1, ISGF3, IRF1 and NF-kappaB). Finally, we screened psoriasis-associated SNPs to identify risk alleles that disrupt or engender PRE motifs. This identified possible sites of allele-specific TF/uDBP binding and showed that PREs are disproportionately disrupted by psoriasis risk alleles. CONCLUSIONS: We identified new TF/uDBP candidates and developed an approach that (i) connects transcriptome informatics to cdODN drug development and (ii) enhances our ability to interpret GWAS findings. Disruption of PRE motifs by psoriasis risk alleles may contribute to disease susceptibility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40169-015-0054-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4392043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-43920432015-04-16 Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites Swindell, William R Sarkar, Mrinal K Stuart, Philip E Voorhees, John J Elder, James T Johnston, Andrew Gudjonsson, Johann E Clin Transl Med Research BACKGROUND: Psoriasis is a cytokine-mediated skin disease that can be treated effectively with immunosuppressive biologic agents. These medications, however, are not equally effective in all patients and are poorly suited for treating mild psoriasis. To develop more targeted therapies, interfering with transcription factor (TF) activity is a promising strategy. METHODS: Meta-analysis was used to identify differentially expressed genes (DEGs) in the lesional skin from psoriasis patients (n = 237). We compiled a dictionary of 2935 binding sites representing empirically-determined binding affinities of TFs and unconventional DNA-binding proteins (uDBPs). This dictionary was screened to identify “psoriasis response elements” (PREs) overrepresented in sequences upstream of psoriasis DEGs. RESULTS: PREs are recognized by IRF1, ISGF3, NF-kappaB and multiple TFs with helix-turn-helix (homeo) or other all-alpha-helical (high-mobility group) DNA-binding domains. We identified a limited set of DEGs that encode proteins interacting with PRE motifs, including TFs (GATA3, EHF, FOXM1, SOX5) and uDBPs (AVEN, RBM8A, GPAM, WISP2). PREs were prominent within enhancer regions near cytokine-encoding DEGs (IL17A, IL19 and IL1B), suggesting that PREs might be incorporated into complex decoy oligonucleotides (cdODNs). To illustrate this idea, we designed a cdODN to concomitantly target psoriasis-activated TFs (i.e., FOXM1, ISGF3, IRF1 and NF-kappaB). Finally, we screened psoriasis-associated SNPs to identify risk alleles that disrupt or engender PRE motifs. This identified possible sites of allele-specific TF/uDBP binding and showed that PREs are disproportionately disrupted by psoriasis risk alleles. CONCLUSIONS: We identified new TF/uDBP candidates and developed an approach that (i) connects transcriptome informatics to cdODN drug development and (ii) enhances our ability to interpret GWAS findings. Disruption of PRE motifs by psoriasis risk alleles may contribute to disease susceptibility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40169-015-0054-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-03-19 /pmc/articles/PMC4392043/ /pubmed/25883770 http://dx.doi.org/10.1186/s40169-015-0054-5 Text en © Swindell et al.; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Swindell, William R Sarkar, Mrinal K Stuart, Philip E Voorhees, John J Elder, James T Johnston, Andrew Gudjonsson, Johann E Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites |
title | Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites |
title_full | Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites |
title_fullStr | Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites |
title_full_unstemmed | Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites |
title_short | Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites |
title_sort | psoriasis drug development and gwas interpretation through in silico analysis of transcription factor binding sites |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392043/ https://www.ncbi.nlm.nih.gov/pubmed/25883770 http://dx.doi.org/10.1186/s40169-015-0054-5 |
work_keys_str_mv | AT swindellwilliamr psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites AT sarkarmrinalk psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites AT stuartphilipe psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites AT voorheesjohnj psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites AT elderjamest psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites AT johnstonandrew psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites AT gudjonssonjohanne psoriasisdrugdevelopmentandgwasinterpretationthroughinsilicoanalysisoftranscriptionfactorbindingsites |